Navigation Links
KaloBios Reports First Quarter 2013 Financial Results

SOUTH SAN FRANCISCO, Calif., May 14, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) a biopharmaceutical company with a portfolio of patient-targeted, first-in-class, antibodies to treat serious medical conditions with a primary clinical focus on respiratory diseases and cancer, announced today its financial results for the first quarter ended March 31, 2013.


"KaloBios marked the first quarter of 2013 with an important milestone in our company's evolution: the successful completion of our initial public offering, with net proceeds to KaloBios of approximately $62 million," said David Pritchard, KaloBios President and Chief Executive Officer. "We also achieved an important clinical milestone this quarter with the start of a Phase 2 trial of KB001-A, our targeted agent against Pseudomonas aeruginosa (Pa), in patients with cystic fibrosis. We were pleased to announce shortly after the quarter's end our partner Sanofi Pasteur's receipt from the U.S. Food and Drug Administration of Fast Track Designation for KB001-A intended for protection against bacterial pneumonia caused by Pa in mechanically ventilated patients.  Finally, in April, we achieved 50% clinical enrollment for our KB003 Phase 2 asthma study putting us on track for top line results in the first quarter of 2014.

The net loss for the first quarter of 2013 was $8.6 million, or $0.55 per basic and diluted share. This compared to a net loss of $1.1 million, or $.56 per basic and diluted share, for the same period in 2012. Increased spending for our clinical trial programs and general and administrative expenses associated with being a public company resulted in the reported loss during the first quarter of 2013.  As of March 31, 2013, cash, cash equivalents and investments, excluding restricted cash, totaled $76.9 million.Company Highlights to Date for 2013January

Initiation of Phase 2 study with KB001-A Humaneered® antibody fragment in cystic fibrosis patientsFebruary

Completion of initial public offeringFebruary

Presentation of positive Phase 1/2 clinical results with anti-GM-CSF mAb KB002 in persistent asthma at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual MeetingApril

Phase 2 study of KB003 in severe asthma achieved 50% enrollmentApril

Sanofi awarded Fast Track Designation for KB001-A for protection against bacterial pneumonia caused by Pa in mechanically-ventilated patients Anticipated Upcoming Milestones for 2013-20142Q 2013:

File for Orphan Drug Status in the U.S.A. and European Union for KB001-A in CF3Q 2013:

Full recruitment of the KB003 asthma study3Q 2013:

Initiation of the Phase 1 expansion phase of the KB004 study in AML with EphA3 diagnostic test4Q 2013:

Full recruitment of the KB001-A CF study 1Q 2014:

Initiation of Phase 2 KB004 study in at least one new indication 1Q 2014:

Top line KB003 Phase 2 asthma study results2Q 2014:

Top line KB001-A Phase 2 CF study results3Q/4Q 2014:

Initiation of Sanofi Phase 2b study for prevention of ventilator-associated pneumonia (VAP) 4Q 2014:

Completion of enrollment in at least one hematologic malignancy indication in the Phase 1 expansion phase of KB004  

About KaloBiosKaloBios Pharmaceuticals, Inc. is developing a portfolio of proprietary, patient-targeted, first-in-class monoclonal antibodies (mAbs) designed to treat serious life-threatening or debilitating disease for which there is an unmet medical need with a clinical focus on serious respiratory diseases and cancer.

Currently, KaloBios has three drug development programs:

  • KB003, an anti-GM-CSF mAb with potential to treat inflammatory diseases, is being developed for the treatment of severe asthma and is currently enrolling patients in a 150 patient Phase 2 study in the United States, Europe and Australia.
  • KB001-A, an anti-PcrV mAb fragment, is partnered exclusively with Sanofi and is being developed for the prevention and treatment of Pseudomonas aeruginosa (Pa) infection. KaloBios has retained rights for the cystic fibrosis (CF) indication and has initiated a 180 patient Phase 2 study in CF subjects with chronic Pa infection in the United States. Sanofi is pursuing a ventilator associated pneumonia prevention indication in the intensive care setting, an indication which has received U.S. FDA Fast Track Designation.
  • KB004, an anti-EphA3 mAb, has potential in treating hematologic malignancies and solid tumors. KaloBios is currently testing this drug in a Phase 1 study in subjects with hematologic malignancies.
  • All of the company's antibodies were generated using its proprietary Humaneered® technology, a method that converts nonhuman antibodies (typically mouse) into recombinant antibodies that have a high binding affinity to their target and are designed for chronic therapeutic use. The company believes that antibodies produced using its Humaneered® technology offer important clinical and economic advantages over antibodies generated by other methods in terms of high binding affinity, high manufacturing yields, and minimal to no immunogenicity (inappropriate immune response) upon repeat administration in humans.

    For more information on KaloBios Pharmaceuticals, please visit our web site at

    Safe Harbor StatementForward Looking Statements
    This release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including:  the statements under the heading "Anticipated Upcoming Milestones for 2013-2014"; and statements regarding the company's clinical development of KB001-A, KB003 and KB004.  Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events.  Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements.  Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the company's limited cash reserves and its ability to obtain additional capital on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that the company has initiated or plans to initiate; the company's dependence on Sanofi Pasteur for the development and commercialization of KB001-A; the company's ability to successfully complete further development of its programs; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; the company's ability to protect the company's intellectual property; competition; changes in the regulatory landscape or the imposition of regulations that affect the company's products; and other factors listed under "Risk Factors" in the company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 1, 2013 and the company's other filings with the Securities and Exchange Commission.

    All forward-looking statements are expressly qualified in their entirety by this cautionary notice.  You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release.  The company has no obligation, and expressly disclaims any obligation to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.

    Contact:Jeffrey H. Cooper
    Chief Financial Officer
    KaloBios Pharmaceuticals, Inc.
    (650) 243-3146

    Media Contact:Joan E. Kureczka
    Kureczka/Martin Associates
    Tel:  (415) 821-2413
    Mobile: (415) 690-0210

    ---- Tables to Follow --

     Consolidated Balance SheetsMarch 31, 2013 and December 31, 2012(in thousands, except share and per share information)March 31,December 31,20132012 (unaudited)  Assets  Current assets:Cash and cash equivalents 

    ,947Marketable securities 

    6,9019,351Contract receivables 

    3487Prepaid expenses and other current assets 

    1,896871  Total current assets 

    78,78021,256  Restricted cash 

    205205  Property and equipment, net 

    193230  Deferred offering costs

    -2,803  Intangible and other assets 

    4145  Total assets 

    24,539  Liabilities, convertible preferred stock and stockholders' equity (deficit)  Current liabilities:Accounts payable 

    2,448Accrued compensation 

    828628Deferred rent, short-term 

    113101Accrued research and clinical liabilities 

    1,3843,538Notes Payable

    811-Other accrued liabilities 

    275502  Total current liabilities 

    9,6107,217  Deferred rent, long-term 

    3162  Notes payable, less current portion

    9,0509,826  Other liabilities, long-term 

    198355  Total liabilities 

    18,88917,460Convertible preferred stock, $0.001 par value: no shares and 60,152,555 shares authorized at March 31, 2013, and  December 31, 2012, respectively;  no shares and  12,329,330 shares issued and outstanding at March 31, 2013, and December 31, 2012, respectively; aggregate liquidation preference of $105,512 at December 31, 2012

    -102,023  Stockholders' equity (deficit): Common stock, $0.001 par value: 80,000,000 shares authorized at March 31, 2013, and December 31, 2012, respectively; 24,147,815 and 2,186,695 shares issued and outstanding at March 31, 2013, and December 31, 2012, respectively

    242Additional paid-in capital 

    167,1433,317Accumulated other comprehensive income

    44Accumulated deficit 

    (106,841)(98,267)  Total stockholders' equity (deficit)

    60,330(94,944)  Total liabilities and stockholders' equity (deficit)

    24,539 Consolidated Statements of OperationsThree Months Ended March 31, 2013 and 2012(in thousands, except share and per share information)(Unaudited)Three Months Ended March 31,20132012Contract revenue $ 16$ 3,018Operating expenses: Research and development 6,3203,220General and administrative 2,019945Total operating expenses 8,3394,165Loss from operations (8,323)(1,147)Other income (expense): Interest income (expense), net(252)6Other income (expense), net 110Net loss$ (8,574)$ (1,131)Basic and diluted net loss per common share$ (0.55)$ (0.56)Weighted average common shares outstanding used to calculate basic and diluted net loss per common share15,607,3792,023,285 Stock based Compensation ExpenseThree Months Ended March 31, 2013 and 2012(in thousands)(Unaudited)Total stock-based compensation expense included in the consolidated statements of operations is as follows:Three Months Ended March 31,20132012Research and development $ 96$ 12General and administrative 859Total stock-based compensation expense$ 181$ 21 

    SOURCE KaloBios Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. KaloBios Pharmaceuticals Announces Pricing of Initial Public Offering
    2. KaloBios Pharmaceuticals Completes Initial Public Offering
    3. KaloBios Presents Clinical Results with Anti-GM-CSF Antibody in Persistent Asthma Data from KB002 Phase 1/2 Study Presented at the American Academy of Allergy, Asthma and Immunology Meeting
    4. KaloBios Presents Clinical Results with Anti-GM-CSF Antibody in Persistent Asthma
    5. Bioassociate Announces Initiation of Coverage on KaloBios Pharmaceuticals, Inc.
    6. KaloBios to Present at Future Leaders in the Biotech Industry Conference
    7. KaloBios Targeted Antibacterial KB001-A to be Featured in BIO 2013 Panel Discussion of "New Defenses Against Old Enemies"
    8. KaloBios to Present at Needham Healthcare Conference
    9. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
    10. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
    11. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
    Post Your Comments:
    (Date:11/26/2015)... 26, 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in ... Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new ... Italian therapeutic drug monitoring market, including emerging tests, ...
    (Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... announced the addition of the  "2016 ... the European Cell Surface Marker Testing ... Opportunities"  report to their offering.  ... the addition of the  "2016 Future ...
    (Date:11/25/2015)... 26, 2015  The total global healthcare industry is expected ... Latin America has the highest projected ... Japan ), is second with growth projected ... face increased healthcare expenditure. In 2013-2014, total government funded healthcare ... in 2008-2009 to 41.2% in 2013-2014. In real terms, out ...
    Breaking Medicine Technology:
    (Date:11/27/2015)... CA (PRWEB) , ... November 27, 2015 , ... According ... at the recent 2015 American Dental Association meeting in Washington D.C. revolved around the ... protect a patient’s overall health. The talk stressed the link between periodontal disease (more ...
    (Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss doctors has released ... Surviving Mesothelioma has just posted the findings on the website. Click here to ... cases of 136 mesothelioma patients who were treated with chemotherapy followed by EPP surgery. ...
    (Date:11/27/2015)... ... November 27, 2015 , ... ... edition of USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, with ... digital component is distributed nationally, through a vast social media strategy and across ...
    (Date:11/27/2015)... ... November 27, 2015 , ... ... well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official group for ... of Microsoft Dynamics SL software users, partners, industry experts and representatives. Intellitec Solutions’ ...
    (Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... CBD ... Accreditation of Allied Health Education Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography ... CAAHEP accredited colleges, as only one of twelve colleges and universities in the state ...
    Breaking Medicine News(10 mins):